Catherine Hackett is editor of MDedge's Cardiology News and Clinical Endocrinology News. She joined the company in 2003. Before that, she was a researcher and managing editor for Time-Life Books, a fact checker for Smithsonian Magazine, and a technical editor at the American Journal of Clinical Nutrition.
News
Preview of ADA/EASD statement on hyperglycemia
- Author:
- Catherine Hackett
A draft of the next ADA/EASD consensus statement on the management of hyperglycemia in type 2 diabetes will be...
News
Clinical trials to look for at ADA 2018
- Author:
- Catherine Hackett
A look at the top clinical research to be presented at ADA 2018 in Orlando.
News
Boston and beyond: Stay connected at #AACE2018
- Author:
- Catherine Hackett
No one is immune from the pull of colleagues past, present, and even future. Here’s how to make the most of networking at AACE 2018.
News
AACE 2018: A dream team of presenters
- Author:
- Catherine Hackett
An array of potentially practice-enhancing presentations at AACE 2018.
News
Original research expands at AACE 2018
- Author:
- Catherine Hackett
With more than 1,000 abstracts, this year’s meeting of the American Association of Clinical Endocrinologists is breaking records
News
First reversal agent for apixaban and rivaroxaban gets fast-track approval
- Author:
- Catherine Hackett
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
News
ACC Day 3: Finishing strong in Late-Breaking Clinical Trial Sessions
- Author:
- Catherine Hackett
Barbershops and anticoagulant reversal agents: ACC 18 vice chair Andrew Kates, MD, highlights two late-breakers.
News
ACC Day 2: Late-Breaking Clinical Trial highlights
- Author:
- Catherine Hackett
Long-term outcomes of a novel heart pump and a look at what happens when copays go away, will be revealed on Sunday.
News
ACC Late-Breaking Clinical Trial sessions preview for day 1
- Author:
- Catherine Hackett
Saturday features reports on two highly anticipated trials, ODYSSEY and VEST.
News
Poststroke depression raises risk of cerebrovascular death 35-fold
- Author:
- Catherine Hackett
Depression after a stroke is deadly and should be monitored and treated.
News
Novel agent to be studied in relapsed/refractory AML
- Author:
- Catherine Hackett
The phase 1b/2 trial will study a polo-like kinase 1 inhibitor.
News
Start with fitness when deciding on treatment for elderly AML patients
- Author:
- Catherine Hackett
In this difficult-to-treat population, fitness assessments help.
News
Late-Breaking Science preview: Wednesday, Nov. 15
- Author:
- Catherine Hackett
Wednesday at AHA is worth sticking around for, if you like innovation.
News
Late-Breaking Science preview: Tuesday, Nov. 14
- Author:
- Catherine Hackett
Antithrombotic therapy is the focus of the Late-Breaking Science 5 presentation.
News
Late-Breaking Science preview: Monday, Nov. 13
- Author:
- Catherine Hackett
Monday at AHA is packed with three Late-Breaking Science sessions, with many presentations providing new insights into blockbuster megatrials.